Anticancer Identification and Molecular Docking of Cowanol from Garcinia fusca Against Histone Deacetylase Domains
DOI:
https://doi.org/10.48048/tis.2024.7807Keywords:
ADME, Cowanol, Garcinia fusca, Histone deacetylase inhibitor, In silico docking, LeukemiaAbstract
The inhibition of HDAC activity is presently one of the main targets for anticancer drug development. This study aimed to investigate the anticancer effect of cowanol via inhibition of HDAC and apoptosis induction in leukemic Jurkat cells. Computational analysis and HDAC inhibitor screening assays were used to determine the properties of cowanol as an HDAC inhibitor in Jurkat cells. MTT assays and Hoechst staining were performed to observe the cytotoxicity and apoptotic induction effect of cowanol. In silico docking analysis revealed that cowanol could tightly bind to the active sites of both HDAC class I (HDAC 2 and 8) and HDAC class II (HDAC 4 and 7) with a similar mode of binding to the reference inhibitors. Importantly, cowanol obviously interacts with the zinc ion at the catalytic center as well as with other amino acid residues in the active region, indicating its possible function as an HDAC inhibitor. The ADME results showed that cowanol possessed acceptable pharmacokinetics and drug-likeness properties, which suggested oral bioavailability. In addition, the screening assay demonstrated that cowanol could inhibit HDAC at 20 - 60 % compared to the standard HDAC inhibitor, SAHA. Moreover, the cytotoxic effect of cowanol against Jurkat cells with the IC50 was 18.19 ± 0.44 µM. For the mode of cell death, nuclear condensation and apoptotic bodies were characterized, supporting the role of the apoptosis inducer cowanol. Hence, our results indicated a potential new role of cowanol as an HDAC inhibitor. The cytotoxic mode of cowanol was illustrated as apoptotic inducer, which is a well-known target for anticancer drug development.
HIGHLIGHTS
- Cowanol has potential effects as HDAC inhibitor and apoptosis inducer
- Cowanol can interact with amino acid residues in the catalytic pocket domain of both HDAC classes I (HDAC 2, 8) and II (HDAC4, 7) proteins
- Cowanol decreased the expression of HDAC enzymes
- Cowanol inhibited cancer progression by promoting nuclear changes and apoptosis in leukemia Jurkat cells
GRAPHICAL ABSTRACT
Downloads
Metrics
References
LJ Castro-Munoz, EV Ulloa, C Sahlgren, M Lizano, EDL Cruz-Hernandez and A Contreras-Paredes. Modulating epigenetic modifications for cancer therapy (Review). Oncol. Rep. 2023; 49, 59.
G Li, Y Tian and WG Zhu. The roles of histone deacetylases and their inhibitors in cancer therapy. Front. Cell Dev. Biol. 2020; 8, 576946.
Z Rana, JDA Tyndall, M Hanif, CG Hartinger and RJ Rosengren. Cytostatic action of novel histone deacetylase inhibitors in androgen receptor-null prostate cancer cells. Pharmaceuticals 2021; 14, 103.
H Mamdani and SI Jalal. Histone deacetylase inhibition in non-small cell lung cancer: Hype or hope? Front. Cell Dev. Biol. 2020; 8, 582370.
T Liang, F Wang, R M Elhassan, Y Cheng, X Tang, W Chen, H Fang and X Hou. Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharm. Sin. B 2023; 13, 2425-63.
N Garmpis, C Damaskos, D Dimitroulis, G Kouraklis, A Garmpi, P Sarantis, E Koustas, A Patsouras, I Psilopatis, EA Antoniou, MV Karamouzis, K Kontzoglou, A Nonni and A Nonni. Clinical significance of the histone deacetylase 2 (HDAC-2) expression in human breast cancer. J. Pers. Med. 2022; 12, 1672.
H Jo, K Shim, HU Kim, HS Jung and D Jeoung. HDAC2 as a target for developing anti-cancer drugs. Comput. Struct. Biotechnol. J. 2023; 21, 2048-57.
JY Kim, H Cho, J Yoo, GW Kim, YH Jeon, SW Lee and SH Kwon. HDAC8 deacetylates HIF-1alpha and enhances its protein stability to promote tumor growth and migration in melanoma. Cancers 2023; 15, 1123.
JY Kim, H Cho, J Yoo, GW Kim, YH Jeon, SW Lee and SH Kwon. Pathological role of HDAC8: Cancer and beyond. Cells 2022; 11, 3161.
M Zhou, M Yuan, M Zhang, C Lei, O Aras, X Zhang and F An. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. Eur. J. Med. Chem. 2021; 226, 113825.
S Kaennakam, E R Sukandar, P Phasuthan, J Yahuafai, P Onsrisawat, F Mulya, V Parasuk, P Phuwapraisirisan and S Tip-Pyang. Garcowacinols A-J, cytotoxic polyprenylated benzoylphloroglucinol derivatives from the twigs of Garcinia cowa. Phytochemistry 2023; 209, 113622.
IP Dewi, FS Wahyuni, Y Aldi, NH Ismail and Dachriyanus. In vitro immunomodulatory activity study of Garcinia cowa Roxb. fraction. J. Compl. Integr. Med. 2023; 20, 365-71.
A Chouni and S Paul. A comprehensive review of the phytochemical and pharmacological potential of an evergreen plant Garcinia cowa. Chem. Biodivers. 2023; 20, e202200910.
J Tauchen, A Frankova, A Manourova, I Valterova, B Lojka and O Leuner. Garcinia kola: A critical review on chemistry and pharmacology of an important West African medicinal plant. Phytochem. Rev. 2023; 22, 1305-51.
PFS Etet, MA Hamza, A El-Tahir, L Vecchio, SY Osman, GMH Satti, MHA Ismail, M Farahna, AK Njamnshi and A Adem. An eluate of the medicinal plant garcinia kola displays strong antidiabetic and neuroprotective properties in streptozotocin-induced diabetic mice. Evid. Based Compl. Alternative Med. 2022; 2022, 8708961.
SD Vita, M Masullo, S Grambone, PB Bescós, S Piacente and G Bifulco. Demethylcalabaxanthone from garcinia mangostana exerts antioxidant effects through the activation of the Nrf2 pathway as assessed via molecular docking and biological evaluation. Antioxidants 2023; 12, 1980.
P Patil, M Agrawal, S Almelkar, M K Jeengar, A More, K Alagarasu, NV Kumar, PS Mainkar, D Parashar and S Cherian. In vitro and in vivo studies reveal alpha-mangostin, a xanthonoid from Garcinia mangostana, as a promising natural antiviral compound against chikungunya virus. Virol. J. 2021; 18, 47.
A Saenkham, A Jaratrungtawee, Y Siriwattanasathien, P Boonsri, K Chainok, A Suksamrarn, M Namsa-Aid, P Pattanaprateeb and S Suksamrarn. Highly potent cholinesterase inhibition of geranylated xanthones from Garcinia fusca and molecular docking studies. Fitoterapia 2020; 146, 104637.
S Punpai, A Saenkham, F Jarintanan, S Jongrungruangchok, K Choowongkomon, S Suksamrarn and W Tanechpongtamb. HDAC inhibitor cowanin extracted from G. fusca induces apoptosis and autophagy via inhibition of the PI3K/Akt/mTOR pathways in Jurkat cells. Biomed. Pharmacother. 2022; 147, 112577.
S Punpai, A Saenkham, K Choowongkomon, S Suksamrarn and W Tanechpongtamb. In silico and in vitro analysis of the role of cowaxanthone as a histone deacetylase inhibitor and apoptosis inducer in human leukemic T-cells. J. Curr. Sci. Tech. 2020; 10, 183-94.
BLSDE Santo, LF Santana, WHK Junior, FDOD Araújo, D Bogo, KDC Freitas, RDCA Guimarães, PA Hiane, A Pott, WFDO Filiú, MA Asato, PDO Figueiredo and PRHDO Bastos. Medicinal potential of garcinia species and their compounds. Molecules 2020; 25, 4513.
VA Tran, TTT Vo, MNT Nguyen, ND Dat, VD Doan, TQ Nguyen, QH Vu, VT Le and TD Tong. Novel α-mangostin derivatives from mangosteen (Garcinia mangostana L.) peel extract with antioxidant and anticancer potential. J. Chem. 2021; 2021, 9985604.
LD Ha, PE Hansen, O Vang, F Duus, HD Pham and LH Nguyen. Cytotoxic geranylated xanthones and O-alkylated derivatives of alpha-mangostin. Chem. Pharm. Bull. 2009; 57, 830-4.
EF Bulbul, J Melesina, HS Ibrahim, M Abdelsalam, A Vecchio, D Robaa, M Zessin, M Schutkowski and W Sippl. Docking, binding free energy calculations and in vitro characterization of pyrazine linked 2-aminobenzamides as novel class i histone deacetylase (HDAC) inhibitors. Molecules 2022; 27, 2526.
A Maruca, R Rocca, R Catalano, F Mesiti, G Costa, D Lanzillotta, A Salatino, F Ortuso, F Trapasso, S Alcaro and A Artese. Natural products extracted from fungal species as new potential anti-cancer drugs: A structure-based drug repurposing approach targeting HDAC7. Molecules 2020; 25, 5524.
N Jansch, KL Lang and FJ Meyer-Almes. Methionine 274 is not the determining factor for selective inhibition of histone deacetylase 8 (HDAC8) by L-shaped inhibitors. Int. J. Mol. Sci. 2022; 23, 11775.
B Scafuri, P Bontempo, L Altucci, LD Masi and A Facchiano. Molecular docking simulations on histone deacetylases (HDAC)-1 and -2 to investigate the flavone binding. Biomedicines 2020; 8, 568.
RD Hernandez, FAF Genio, JR Casanova, MT Conato and MC Paderes. Antiproliferative activities and swissADME predictions of physicochemical properties of carbonyl group-modified rotenone analogues. ChemistryOpen 2023; 13, e202300087.
CPMD Silva, GMD Neves, GLV Poser, VL Eifler-Lima and SMK Rates. In silico prediction of ADMET/Drug-likeness properties of bioactive phloroglucinols from hypericum genus. Med. Chem. 2023; 19, 1002-17.
A Drakontaeidi and E Pontiki. A review on molecular docking on HDAC isoforms: Novel tool for designing selective inhibitors. Pharmaceuticals 2023; 16, 1639.
AI Uba and G Zengin. Phenolic compounds as histone deacetylase inhibitors: Binding propensity and interaction insights from molecular docking and dynamics simulations. Amino Acids. 2023; 55, 579-93.
A Schuetz, J Min, A Allali-Hassani, M Schapira, M Shuen, P Loppnau, R Mazitschek, NP Kwiatkowski, TA Lewis, RL Maglathin, TH McLean, A Bochkarev, AN Plotnikov, M Vedadi and CH Arrowsmith. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem. 2008; 283, 11355-63.
F Desantis, M Miotto, LD Rienzo, E Milanetti and G Ruocco. Spatial organization of hydrophobic and charged residues affects protein thermal stability and binding affinity. Sci. Rep. 2022; 12, 12087.
Y Kawasaki, EE Chufan, V Lafont, K Hidaka, Y Kiso, LM Amzel and E Freire. How much binding affinity can be gained by filling a cavity? Chem. Biol. Drug Des. 2010; 75, 143-51.
S Cho, CP Swaminathan, J Yang, MC Kerzic, R Guan, MC Kieke, DM Kranz, RA Mariuzza and EJ Sundberg. Structural basis of affinity maturation and intramolecular cooperativity in a protein-protein interaction. Structure 2005; 13, 1775-87.
R Leechaisit, P Mahalapbutr, P Boonsri, K Karnchanapandh, T Rungrotmongkol, V Prachayasittikul, S Prachayasittikul, S Ruchirawat, V Prachayasittikul and R Pingaew. Discovery of novel naphthoquinone-chalcone hybrids as potent FGFR1 tyrosine kinase inhibitors: Synthesis, biological evaluation, and molecular modeling. ACS Omega 2023; 8, 32593-605.
P Mahalapbutr, R Leechaisit, A Thongnum, D Todsaporn, V Prachayasittikul, T Rungrotmongkol, S Prachayasittikul, S Ruchirawat and V Prachayasittikul and R Pingaew. Discovery of anilino-1,4-naphthoquinones as potent EGFR tyrosine kinase inhibitors: Synthesis, biological evaluation, and comprehensive molecular modeling. ACS Omega 2022; 7, 17881-93.
K Matsumoto, Y Akao, E Kobayashi, K Ohguchi, T Ito, T Tanaka, M Iinuma and Y Nozawa. Induction of apoptosis by xanthones from mangosteen in human leukemia cell lines. J. Nat. Prod. 2003; 66, 1124-7.
FAA Omer, NBM Hashim, MY Ibrahim, F Dehghan, M Yahayu, H Karimian, . . ., S Mohan. Beta-mangostin from Cratoxylum arborescens activates the intrinsic apoptosis pathway through reactive oxygen species with downregulation of the HSP70 gene in the HL60 cells associated with a G0/G1 cell-cycle arrest. Tumor Biol. 2017; 39, 1010428317731451.
K Matsumoto, Y Akao, H Yi, K Ohguchi, T Ito, T Tanaka, E Kobayashi, M Iinuma and Y Nozawa. Preferential target is mitochondria in alpha-mangostin-induced apoptosis in human leukemia HL60 cells. Bioorg. Med. Chem. 2004; 12, 5799-806.
A Berger, S Venturelli, M Kallnischkies, A Bocker, C Busch, T Weiland, S Noor, C Leischner, TS Weiss, UM Lauer, SC Bischoff and M Bitzer. Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases. J. Nutr. Biochem. 2013; 24, 977-85.
S Venturelli, A Berger, A Bocker, C Busch, T Weiland, S Noor, C Leischner, S Schleicher, M Mayer, TS Weiss, SC Bischoff, UM Lauer and M Bitzer. Resveratrol as a pan-HDAC inhibitor alters the acetylation status of histone [corrected] proteins in human-derived hepatoblastoma cells. PLoS One. 2013; 8, e73097.
A Kalaiarasi, C Anusha, R Sankar, S Rajasekaran, J John Marshal, K Muthusamy and V Ravikumar. Plant isoquinoline alkaloid berberine exhibits chromatin remodeling by modulation of histone deacetylase to induce growth arrest and apoptosis in the A549 cell line. J. Agric. Food Chem. 2016; 64, 9542-50.
Z Tang, L Lu and Z Xia. Anti-tumor xanthones from garcinia nujiangensis suppress proliferation, and induce apoptosis via PARP, PI3K/AKT/mTOR, and MAPK/ERK signaling pathways in human ovarian cancers cells. Drug Des. Devel. Ther. 2020; 14, 3965-76.
Y Li, H Wang, W Liu, J Hou, J Xu, Y Guo and P Hu. Cratoxylumxanthone C, a natural xanthone, inhibits lung cancer proliferation and metastasis by regulating STAT3 and FAK signal pathways. Front. Pharmacol. 2022; 13, 920422.
H Zhang, YP Tan, L Zhao, L Wang, NJ Fu, SP Zheng and XF Shen. Anticancer activity of dietary xanthone alpha-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1. Cell Death Dis. 2020; 11, 63.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Walailak University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
